BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28177521)

  • 1. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma.
    Ansari D; Bauden M; Bergström S; Rylance R; Marko-Varga G; Andersson R
    Br J Surg; 2017 Apr; 104(5):600-607. PubMed ID: 28177521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis.
    Meng Z; Cao M; Zhang Y; Liu Z; Wu S; Wu H
    BMC Gastroenterol; 2019 Apr; 19(1):59. PubMed ID: 31014264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
    Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
    Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening.
    Hur C; Tramontano AC; Dowling EC; Brooks GA; Jeon A; Brugge WR; Gazelle GS; Kong CY; Pandharipande PV
    Pancreas; 2016 Aug; 45(7):1062-6. PubMed ID: 26692444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
    Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
    J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
    van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
    Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
    Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
    Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
    Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
    Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
    Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of Recently Diagnosed Diabetes and Long-term Diabetes With Survival in Pancreatic Cancer Patients: A Pooled Analysis.
    Jeon CY; Li D; Cleary S; Stolzenberg-Solomon R; Bosetti C; La Vecchia C; Porta M; Toriola AT; Hung RJ; Kurtz RC; Olson SH
    Pancreas; 2018 Mar; 47(3):314-320. PubMed ID: 29401167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
    Rochefort MM; Ankeny JS; Kadera BE; Donald GW; Isacoff W; Wainberg ZA; Hines OJ; Donahue TR; Reber HA; Tomlinson JS
    Ann Surg Oncol; 2013 Dec; 20(13):4322-9. PubMed ID: 23943022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the molecular pathology of pancreatic body and tail adenocarcinoma.
    Dreyer SB; Jamieson NB; Upstill-Goddard R; Bailey PJ; McKay CJ; ; Biankin AV; Chang DK
    Br J Surg; 2018 Jan; 105(2):e183-e191. PubMed ID: 29341146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma.
    Ding YC; Yu W; Ma C; Wang Q; Huang CS; Huang T
    Int J Clin Exp Pathol; 2014; 7(11):8065-70. PubMed ID: 25550852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with resected, histologically re-confirmed pancreatic ductal adenocarcinoma (PDAC) can achieve long-term survival despite T3 tumour or nodal involvement. The Finnish Register Study 2000-2013.
    Ahola R; Siiki A; Vasama K; Vornanen M; Sand J; Laukkarinen J
    Pancreatology; 2017; 17(5):822-826. PubMed ID: 28789903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.
    Chen YT; Huang ZP; Zhou ZW; He MM
    Med Oncol; 2016 Nov; 33(11):122. PubMed ID: 27730526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.